Literature DB >> 20053332

Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Eric C Walter1, Mauricio Orozco-Levi, Alba Ramirez-Sarmiento, Afonso Vigorito, Paulo V Campregher, Paul J Martin, Mary E Flowers, Jason W Chien.   

Abstract

It is unknown if diminished pulmonary function early after allogeneic hematopoietic transplant is associated with poor long-term outcomes. The objective of this study was to determine if posttransplant lung function is associated with 5-year nonrelapse mortality (NRM) and the development of chronic graft-versus-host disease (cGVHD). Retrospective analysis was done for 2158 patients who had routine pulmonary function testing 60-120 days after transplant between 1992 and 2004. Cox regression was used to assess the hazard ratio for 5-year NRM. A second analysis assessed the hazard ratio for the development of cGVHD. Lung function score was the primary exposure, and was calculated according to forced expiratory volume in 1 second (FEV(1)) and carbon monoxide diffusion capapcity (DLCO). Individual pulmonary function parameters were secondary exposures. The primary outcomes were 5-year NRM and the development of cGVHD. Most patients had normal lung function following transplant. A higher lung function score, signifying greater impairment, was associated with an increased risk of mortality (category 1 hazard ratio [HR] 1.47 [1.17-1.85]; category 2 HR 3.38 [2.53-4.53]; category 3 HR 7.80 [4.15-14.68]). A similar association was observed for all individual pulmonary function parameters. Low FEV(1) was associated with the subsequent development of cGVHD (FEV(1) 70%-79% HR 1.26 [1.01-1.57]; 60%-69% HR 1.48 [1.10-2.01]; <60% HR 2.02 [1.34-3.05]). Models using either lung function score or individual pulmonary function parameters performed about equally well as judged by the C-statistic. Impaired lung function at day 80 posttransplant was associated with a higher risk of NRM. A low FEV(1) following transplant was associated with developing cGVHD within 1 year. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20053332      PMCID: PMC2804923          DOI: 10.1016/j.bbmt.2009.08.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  22 in total

1.  Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1991-11

2.  Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1987-11

3.  Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia.

Authors:  T G Sutedja; J F Apperley; J M Hughes; V R Aber; H G Kennedy; P Nunn; L Jones; L Hopper; J M Goldman
Journal:  Thorax       Date:  1988-03       Impact factor: 9.139

Review 4.  Radiation-induced and chemotherapy-induced pulmonary injury.

Authors:  S H Abid; V Malhotra; M C Perry
Journal:  Curr Opin Oncol       Date:  2001-07       Impact factor: 3.645

5.  Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Jason W Chien; Paul J Martin; Ted A Gooley; Mary E Flowers; Susan R Heckbert; W Garrett Nichols; Joan G Clark
Journal:  Am J Respir Crit Care Med       Date:  2003-03-20       Impact factor: 21.405

Review 6.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

7.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

8.  Pulmonary function changes in long-term survivors of chronic myelogenous leukemia after allogeneic bone marrow transplantation: a Taiwan experience.

Authors:  Tzeon-Jye Chiou; Shiao-Lin Tung; Wei-Shu Wang; Woan-Fang Tzeng; Chueh-Chuan Yen; Frank S Fan; Jin-Hwang Liu; Po-Min Chen
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

9.  Diffusion capacity predicts long-term survival after allogeneic bone marrow transplantation for acute lymphoblastic leukemia.

Authors:  Peter Mu-Hsin Chang; Tzeon-Jye Chiou; Chueh-Chuan Yen; Liang-Tsai Hsiao; Jin-Hwang Liu; Po-Min Chen
Journal:  J Chin Med Assoc       Date:  2008-05       Impact factor: 2.743

10.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

Authors:  Kieren A Marr; Rachel A Carter; Michael Boeckh; Paul Martin; Lawrence Corey
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

View more
  15 in total

1.  Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation.

Authors:  Racquel Domingo-Gonzalez; Carol A Wilke; Steven K Huang; Yasmina Laouar; Jeanette P Brown; Christine M Freeman; Jeffrey L Curtis; Gregory A Yanik; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

2.  Lung function before and after pediatric allogeneic hematopoietic stem cell transplantation: a predictive role for DLCOa/VA.

Authors:  Troy C Quigg; Young-Jee Kim; W Scott Goebel; Paul R Haut
Journal:  J Pediatr Hematol Oncol       Date:  2012-05       Impact factor: 1.289

Review 3.  How I treat acute myeloid leukemia presenting with preexisting comorbidities.

Authors:  Yishai Ofran; Martin S Tallman; Jacob M Rowe
Journal:  Blood       Date:  2016-05-27       Impact factor: 22.113

4.  Cigarette smoking and outcomes after allogeneic hematopoietic stem cell transplantation.

Authors:  Betty T Tran; Abigail Halperin; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2011-03-29       Impact factor: 5.742

5.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

Authors:  Sally Arai; Madan Jagasia; Barry Storer; Xiaoyu Chai; Joseph Pidala; Corey Cutler; Mukta Arora; Daniel J Weisdorf; Mary E D Flowers; Paul J Martin; Jeanne Palmer; David Jacobsohn; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

6.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

7.  Stable long-term pulmonary function after myeloablative double cord blood transplant.

Authors:  Filippo Milano; Jason W Chien; Ivy Riffkin; Jonathan A Gutman; Laura Newell; Steven A Pergam; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-11       Impact factor: 5.742

8.  Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Guang-Shing Cheng; Angela P Campbell; Hu Xie; Zach Stednick; Cheryl Callais; Wendy M Leisenring; Janet A Englund; Jason W Chien; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-31       Impact factor: 5.742

9.  Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Authors:  Ana Zelic Kerep; Jacob Broome; Filip Pirsl; Lauren M Curtis; Seth M Steinberg; Sandra A Mitchell; Edward W Cowen; Dominique C Pichard; Galen O Joe; Leora E Comis; Jacqueline W Mays; Manuel B Datiles; Pamela Stratton; Jessica Zolton; Ann Berger; Jennifer Hendricks; Megan Kenyon; Judy Baruffaldi; Irina Titarenko; Drazen Pulanic; Kristin Baird; Daniel H Fowler; Ronald E Gress; Steven Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2018-08-08       Impact factor: 5.483

10.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Authors:  S Dirou; F Malard; A Chambellan; P Chevallier; P Germaud; T Guillaume; J Delaunay; P Moreau; B Delasalle; P Lemarchand; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.